Plain-English fact sheet
Liraglutide
Also known as Victoza, Saxenda
Liraglutide is a GLP-1 receptor agonist with strong human evidence for the uses described in its FDA-approved product labels.
Quick answer
Liraglutide is FDA approved in products for type 2 diabetes and chronic weight management. Approval and age criteria depend on the exact product label.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Liraglutide?
Liraglutide is a manufactured GLP-1 analog. It acts on a receptor involved in blood-sugar regulation, appetite, and digestion.
Victoza and Saxenda contain liraglutide but have different labeled uses and should not be treated as a single generic claim.
Why are people interested in it?
Liraglutide has a longer clinical history than several newer incretin medicines.
Readers often compare its evidence, schedule, outcomes, and risks with semaglutide and tirzepatide.
Current regulatory status
FDA-approved liraglutide products have indications for type 2 diabetes or chronic weight management in defined populations. Check current labeling for age and eligibility details.
What is it approved for?
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults and adolescents
- Reducing specified cardiovascular risks under the applicable label
What is it being studied for?
Investigational areas
- Other metabolic outcomes outside current labels
Evidence snapshot
Large clinical programs support approved uses, including cardiovascular outcomes evidence in a labeled diabetes population.
Potential benefits being researched
- Controlled trials support benefits for blood-sugar control and chronic weight management in labeled populations.
- The amount and type of benefit differ by population, endpoint, and product indication.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Gastrointestinal effects such as nausea, diarrhea, constipation, and vomiting are common.
- Labels include a boxed warning related to thyroid C-cell tumors in rodents and list important contraindications.
- Other concerns can include pancreatitis, gallbladder disease, kidney problems related to dehydration, and low blood sugar with certain other medicines.
What we still do not know
- How outcomes compare directly across every newer medicine and population
- Whether research outside approved uses will produce meaningful clinical benefits
- Individual benefit-risk tradeoffs that require a clinician's review
Plain-English takeaway
Liraglutide is an established prescription medicine, but its evidence should be discussed by product, labeled use, population, and individual risks—not by class reputation alone.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA Drugs@FDA search: liraglutide
Official FDA approval records, labels, and regulatory history.
- 2FDA prescribing information: Saxenda
Official prescribing information for a liraglutide product.
- 3ClinicalTrials.gov studies: liraglutide
Current and completed registered clinical studies.
- 4PubMed research: liraglutide randomized trial
Peer-reviewed literature indexed by the National Library of Medicine.